Daiichi Sankyo Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Daiichi Sankyo Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Daiichi Sankyo Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Daiichi Sankyo Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers an array of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Daiichi Sankyo Bldg. A/B Kan, 3-5-1, Nihombashi Hon-Cho, Chuo-Ku, Tokyo, 103-8426
Website
www.daiichisankyo.co.jp
Telephone
81 3 62251111
No of Employees
20,171
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4568 (TYO)
Revenue (2025)
$13.6B
12.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-12.1%
(2025 vs 2024)
Market Cap*
$33.8B
Net Profit Margin (2025)
XYZ
-21.9%
(2025 vs 2024)
* As of and is in US$
Daiichi Sankyo Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology: | Olmetec |
| Trastuzumab Deruxtecan | Benicar |
| Pexidartinib | Benicar HCT |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company secured approval for Enhertu (trastuzumab deruxtecan for injection) to use in combination with pertuzumab to treat adult patients with unresectable or metastatic HER2-positive breast cancer in China. |
| 2026 | Regulatory Approval | In May, the company's and AstraZeneca’s Enhertu (trastuzumab deruxtecan) was approved by the US FDA for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. |
| 2026 | Contracts/Agreements | In May, the company partnered with Waiv to develop AI-derived digital pathology biomarkers for an Antibody-Drug Conjugate (ADC) program. |
Competitor Comparison
| Key Parameters | Daiichi Sankyo Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd | Shionogi & Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 20,171 | 47,029 | 14,099 | 7,872 | 4,955 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hiroyuki Okuzawa | Chief Executive Officer; President; Director | Executive Board | 2025 | - |
| Koji Ogawa | Head - Global Corporate Planning and Management; Chief Financial Officer | Senior Management | 2023 | - |
| Matt Allegrucci | Chief Compliance Officer; Head - Global Compliance & Risk Management | Senior Management | 2024 | - |
| Joseph Kenneth Keller | Head - Oncology Business Unit; Director | Executive Board | 2025 | - |
| Takashi Matsumoto | Director; Head- Global Corporate Affairs; Chief Corporate Affairs Officer; Chief Human Resources Officer; Head - Global HR | Executive Board | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer